subunit in the discriminative stimulus effects of ketamine. Behav
Pharmacol 14:229 –235.
Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty
S, Efferen TR, Szilagyi S, Stephanides M, Chappell B, Gonzenbach
S, Ko GN, Rotrosen JP (2001) Clinical and sensorimotor gating
effects of ketamine in normals. Neuropsychopharmacology 25:72–
83.
Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999) Comparison of brain metabolic activity patterns induced by ketamine, MK- 801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res
843:171–183.
Duncan GE, Moy JJ, Knapp DJ, Mueller RA, Breese GR (1998)
Metabolic mapping of the rat brain after subanesthetic doses of
ketamine: potential relevance to schizophrenia. Brain Res 787:
181–190.
Gibson CL, Clowry GJ (2001) N-methyl-D-aspartate receptor blockade
during development induces short-term but not long-term changes
in c-Jun and parvalbumin expression in the rat cervical spinal cord.
Exp Neurol 170:380 –384.
Heckers S, Konradi C (2002) Hippocampal neurons in schizophrenia.
J Neural Transm 109:891–905.
Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM (2002)
Differential hippocampal expression of glutamic acid decarboxylase
65 and 67 messenger RNA in bipolar disorder schizophrenia. Arch
Gen Psychiatry 59:521–529.
Herdegen T, Kovary K, Buhl A, Bravo R, Zimmermann M, Gass P
(1995) Basal expression of the inducible transcription factors c-Jun,
JunB, JunD, c-Fos, FosB, and Krox-24 in the adult rat brain.
J Comp Neuol 354:39 –56.
Herken H, Uz E, Ozyurt H, Akyol O (2001) Red blood cell nitric oxide
levels in patients with schizophrenia. Schizophr Res 52:289 –290.
Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R (2003) Pharmacokinetics and haemodynamics of ketamine in intensive care pa- tients with brain or spinal cord injury. Br J Anaesth 90:155–160.
Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and
PCP have direct effects on the dopamine D(2) and serotonin
5-HT(2)receptors-implications for models of schizophrenia. Mol
Psychiatry 7:837–844.
Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann
JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000)
Modulation of amphetamine-induced striatal dopamine release by
ketamine in humans: implications for schizophrenia. Biol Psychiatry
48:627–640.
Kontkanen O, Lakso M, Wong G, Castren E (2002) Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun
family genes and activator protein 1 complex in the rat prefrontal
cortex. Neuropsychopharmacology 27:152–162.
Lindefors N, Barati S, O'Connor WT (1997) Differential effects of single
and repeated ketamine administration on dopamine, serotonin and
GABA transmission in rat medial prefrontal cortex. Brain Res 759:
205–212.
Masuzawa M, Nakao S, Miyamoto E, Yamada M, Murao K, Nishi K,
Shingu K (2003) Pentobarbital inhibits ketamine-induced dopamine
release in the rat nucleus accumbens: a microdialysis study.
Anesth Analg 96:148 –152.
Mechri A, Saound M, Khiari G, d'Amato T, Dalery J, Gaha L (2001)
Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine. Encephale 27:53–59.
Mitchell IJ, Cooper AJ, Griffiths MR, Barber DJ (1998) Phencyclidine
and corticosteroids induce apoptosis of a subpopulation of striatal
neurons: a neural substrate for psychosis? Neuroscience 84:489 –
501.
Miyamoto S, Mailman RB, Lieberman JA, Duncan GE (2001) Blunted
brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res 894:167–180.
Moghaddam B, Adams A, Verma A, Daly D (1997) Activation of
glutamatergic neurotransmission by ketamine: a novel step in the
